WHIM syndrome is a rare, inherited, combined immunodeficiency disease caused by reduced mobilization and trafficking of white blood cells from the bone marrow due to over-signaling of the CXCR4/CXCL12 pathway. WHIM syndrome is named for its four common clinical findings. The diagnostic challenges arise because not all symptoms are required for a diagnosis and all of them do not appear at the same time. Patients have deficient blood levels of neutrophils (neutropenia) and lymphocytes (lymphopenia), which results in frequent, recurrent infections. Affected individuals are particularly susceptible to human papillomavirus (HPV), which can cause skin and genital warts and potentially lead to certain types of cancer. Our program goal is to identify risk factors associated with WHIM syndrome, focusing on making an earlier diagnosis that can impact long-term outcomes, timely treatment options and ultimately improved quality of life for patients.
WHIM Syndrome (A Chronic Neutropenic Disorder): Uncouple the Complex for HCPs and Patients
You Don’t Know WHIM Syndrome (A Chronic Neutropenic Disorder)
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following have disclosed:
Jacob R. Bledsoe, MD, faculty for this educational event, receives consulting fees from X4 Pharmaceuticals.Peter E. Newburger, MD, faculty for this educational event, receives consulting fees from X4 Pharmaceuticals.
Teresa K. Tarrant, MD, is a contracted researcher for X4 Pharmaceuticals, Horizon Therapuetics, Amegen, Chiesi USA, and Viela Bio; and receives consulting fees from X4 Pharmaceuticals, Chiesi USA.
Jolan Walter, MD, PHD is a contracted researcher for Takeda, Janssen, Chiesi, MustangBio, ADMA Biologicals, Octapharma, X4-Pharmaceuticals, Novartis, Regeneron, Bristol-Myers Squibb; receives consulting fees from Takeda, X4- Pharmaceuticals, CSL-Behring, Grifols, ADMA Biologicals, Enzyvant, Regeneron, and Pharming; and is a speaker for Takeda, and Pharming.
The following reviewers, managers, planners, and relevant staff reported they do not have any financial relationships with any ineligible companies:
Brian P. McDonough, MD, FAAP, has nothing to disclose.
Prerna Poojary, PhD, has nothing to disclose.
Leticia Samaras has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Gain an understanding of WHIM syndrome as a rare PID/ chronic neutropenic disorder with diverse clinical presentations
- Implement strategic measures to improve the early identification of WHIM syndrome patients for prompt assessment and diagnosis to avoid potential complications and long-term sequelae
- Understand the CXCR4 pathway dysregulation and how it relates to the underlying causes of WHIM syndrome
- Garner an understanding of the limitations of current approaches for WHIM syndrome and potential new approaches for patients
Target Audience
This activity has been designed to meet the educational needs of immunologists and infection disease professionals, as well as primary care physicians, nurses, physician assistants, nurse practitioners, pharmacists, and all other healthcare providers involved in managing patients with WHIM Syndrome, a chronic neutropenic disorder.
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC). GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 CEUs of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-040-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service at custserv@napb.net
Provider(s)/Educational Partner(s)
It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME, LLC is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by an independent educational grant from X4 Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Global Learning Collaborative (GLC) and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
